Adjuvant therapy for surgically resected pancreatic adenocarcinoma.

摘要

The value of therapy following surgical resection of pancreatic adenocarcinoma has been controversial since 1985 following the publication of the first results of the Gastrointestinal Tumor Study Group's (GITSG) underpowered, long-accruing trial.5 That study, involving 43 randomized and analyzed patients, demonstrated a survival of 21 months for patients treated with fluorouracil-based chemoradiation and prolonged treatment with systemic fluorouracil compared with an 11-month survival for patients treated with surgery alone.5 At that time, the rationale for chemoradiation was that the recurrence pattern of resected pancreatic adenocarcinoma involved local recurrences in the pancreatic bed and metastatic failures involving the liver and peritoneal surfaces necessitating protracted administration of systemic flubrouracil.